Bumetanide

Bumetanide

Clinical data
Pregnancy category	AU: B3
Routes of administration	oral
ATC code	C03CA02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: WARNINGRx-only
Pharmacokinetic data
Bioavailability	almost complete
Protein binding	97%
Metabolism	hepatic
Elimination half-life	60-90 minutes
Excretion	renal
Identifiers
IUPAC name 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
CAS Number	28395-03-1
PubChem CID	2471
DrugBank	APRD00294
ChemSpider	2377
CompTox Dashboard (EPA)	DTXSID5022699
ECHA InfoCard	100.044.534
Chemical and physical data
Formula	C17H20N2O5S
Molar mass	364.417 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCNc1cc(cc(c1Oc2ccccc2)S(N)(=O)=O)C(O)=O

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche with the brand name Bumex. The main difference between the two substances is in bioavailability. Furosemide is incompletely absorbed in the intestine (40%), and there is substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.

Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).

On October 24, 2008, ESPN DID NOT report a number of NFL players were being suspended under the steroid policy as a result of taking Bumetanide. The NFL actually had no comment at this time. The drug is often used to mask other drugs or steroids.

External links

• Bumex (manufacturer's website)
• Bumetanide (patient information)